Sacituzumab Govitecan-hziy
Sacituzumab govitecan-hziy is a type of targeted therapy drug called an antibody-drug conjugate. It consists of a monoclonal antibody linked to a toxic drug called SN-38 that binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and blocks an enzyme called topoisomerase I. This damages the DNA of the cancer cells and kills them.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Sacituzumab govitecan-hziy is approved to treat adults with:
- breast cancer that has spread to other parts of the body or cannot be removed by surgery. It is used:
- in patients with triple-negative cancer who have received at least two systemic therapies, including at least one for metastatic cancer
- in patients with hormone receptor–positive and HER2–negative cancer who have received hormone therapy and at least two systemic therapies for metastatic cancer
Sacituzumab govitecan-hziy is also being studied in the treatment of other types of cancer.
More About Sacituzumab Govitecan-hziy
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Sacituzumab Govitecan-hziy - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Sacituzumab Govitecan-hziy - Check for trials from NCI's list of cancer clinical trials now accepting patients.